FDA Pauses New Enrollment in Biohaven's BHV-7000 Epilepsy Trials

Biohaven (NYSE: BHVN) shares fell about 14% to roughly $12.93 on Thursday after the FDA placed a partial clinical hold on BHV-7000, the company’s lead Kv7 epilepsy drug also known as opakalim, pausing new patient enrollment in its two late-stage focal epilepsy trials. For the mechanics of full vs. partial holds and how to parse the 8-K language, see our clinical hold explainer.

Opakalim is a selective Kv7.2/7.3 potassium channel activator, an oral once-daily pill designed to calm overactive neurons without the sedation and dizziness that weigh on older antiseizure drugs. The partial hold, disclosed in a Thursday SEC filing, covers enrollment of new patients in the RISE 2 and RISE 3 Phase 3 studies. The FDA acted so it could evaluate a potential risk to humans from a metabolite identified during rodent testing, and the agency is asking Biohaven to run additional nonclinical studies. Dosing continues for the more than 600 patients already randomized across the two trials.

The impact is uneven across the two studies. Enrollment in RISE 3 was completed in June, and Biohaven said a topline readout remains on track for the second half of 2026. RISE 2 had not finished recruiting, and the pause is likely to delay that readout, RBC Capital Markets wrote Thursday. RISE 2 had previously carried a primary completion date in December.

Biohaven said the significance of the rodent metabolite finding to humans is uncertain and may be specific to rodents rather than relevant to human safety. BHV-7000 has been dosed in more than 1,200 participants and has been generally safe and well-tolerated, the company said.

The hold is the latest setback for the Kv7 program. BHV-7000 missed its primary endpoint in a Phase 2 major depressive disorder study in December 2025, and the FDA rejected Biohaven’s troriluzole for spinocerebellar ataxia in November 2025, prompting a 60% cut to R&D spending. In August, Biohaven licensed the Kv7 platform, including BHV-7000, to SK Biopharmaceuticals in a deal worth up to $795 million, covered here.

The epilepsy field is already crowded with Kv7 rivals. Xenon Pharmaceuticals’ azetukalner, another Kv7 opener, reported positive Phase 3 X-TOLE2 data in March showing a 53.2% reduction in monthly focal seizures, and Xenon is targeting an FDA filing this year. A delayed or derailed RISE 2 readout would hand Xenon more room to move first.

What to watch next: the RISE 3 topline readout in the second half of 2026, which stays on schedule, and whether Biohaven’s additional nonclinical work satisfies the FDA and lifts the hold on RISE 2.

What It Means for the Trade

A 14% drop on a partial hold that pauses new enrollment — while 600-plus already-randomized patients keep dosing and the pivotal RISE 3 readout stays on schedule for H2 2026 — is the market pricing fear, not math. Decompose the event: RISE 3 completed enrollment in June, so its dataset is locked and its topline is unaffected. RISE 2 was still recruiting with a December primary completion date, so the hold delays its readout by however long the FDA takes to evaluate a rodent metabolite question — an increment of uncertainty, not a program kill. The metabolite finding is explicitly flagged as possibly rodent-specific, and more than 1,200 human exposures to date with no related safety signal is the kind of context that often resolves these holds. But “often resolves” is doing real work in that sentence, and the market is right to demand a discount until the FDA’s questions are answered.

The competitive stakes are what turn this from housekeeping into a narrative event. Xenon’s azetukalner posted 53.2% seizure reduction versus 10.4% placebo in X-TOLE2 and is targeting an FDA filing this year — meaning the Kv7 class’s first-mover position is genuinely in play. A delayed RISE 2 hands Xenon a cleaner runway to define the class’s regulatory template; a clean RISE 3 readout on schedule keeps opakalim’s approval timeline roughly intact regardless of what happens to RISE 2. The two Phase 3 trials were always redundancy; the hold stress-tests whether the redundancy actually protects the program.

Mechanism and Program Context

The Kv7 story explains both the promise and the fragility. Kv7.2/7.3 potassium channels are the neuronal braking system — opening them hyperpolarizes the cell and quiets firing without touching GABAergic sedation pathways, which is the entire tolerability pitch against older antiseizure drugs. Selective openers have been the epilepsy field’s white whale for years precisely because the target is validated by biology (SCN2A-adjacent mechanisms, retigabine’s mechanism with retigabine’s tolerability problems) but hard to drug cleanly. A rodent metabolite risk on a molecule already dosed in 1,200 humans with clean tolerability is most likely a species-specific tox artifact — rodent metabolism differs enough from human that metabolite panels routinely diverge — but the FDA asking for additional nonclinical studies means the agency wants the exclusion documented, not assumed.

The bigger context is Biohaven’s string: BHV-7000 missed its MDD Phase 2 primary in December 2025, troriluzole got the CRL in November 2025 with a 60% R&D cut following, and the Kv7 platform was out-licensed to SK Biopharmaceuticals in August for up to $795 million. The partial hold lands on a company that already de-risked its balance sheet exposure to this program — SK funds development from here, and Biohaven’s economics are now upfront cash, milestones, and royalties. That structure cushions the equity downside of a Kv7 stumble, which is a legitimate part of why a 14% drop may overstate the fundamental damage.

Risks and What Could Go Wrong

1. The FDA’s nonclinical requirement expands beyond a three-month delay — a human-relevant metabolite finding would force dose-limiting amendments or worse, and RISE 2’s December timeline slips into 2027.
2. RISE 3’s H2 topline misses or underwhelms: with RISE 2 delayed, there is no second data event to catch the story, and the Kv7 thesis rests on one readout.
3. Xenon files first and launches first, converting a class race into an incumbent-challenger fight with opakalim cast as the late me-too.
4. Biohaven’s remaining pipeline concentration: after troriluzole’s CRL and the Kv7 out-license, the equity story is thinner, and each program-specific headline moves the stock more than it would at a diversified biotech.

Position read: the discount for the hold is probably fair-to-slightly-rich, but the real pricing event is the RISE 3 readout in H2 2026 — unchanged by this news. If you want the binary, the hold-driven weakness is entry logic; if you don’t, there is nothing here that compels a position.

Source: BioSpace · Biohaven SEC filing